Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of California, Los Angeles
With
POM Wonderful LLC
Age
50–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Agreement to participate in the 12-month double-blind, placebo-controlled clinical trial of pomegranate extract.
Nondemented subjects either those with normal cognition or with Mild Cognitive Impairment will be included.
Age 50 to 75 years.
No significant cerebrovascular disease: modified Ischemic Score of \< 4
Adequate visual and auditory acuity to allow neuropsychological testing.
Screening laboratory tests and EKG without significant abnormalities that might interfere with the study. If screening laboratory tests or EKG show abnormalities, subject must obtain written clearance from primary care physician before continuing in the study.
You may not be if
Diagnosis of probable Alzheimer's disease (AD) or any other dementia (e.g., vascular, Lewy body, frontotemporal) (McKhann et al, 1984). Evidence of other neurological or physical illness that can produce cognitive deterioration. Volunteers with a history of stroke, Transient Ischemic Attack (TIA), carotid bruits, or lacunes on MRI scans will be excluded. Determination of dementia will be based on the clinical evaluation including assessment of functional abilities, and cognitive screening.
Contraindication to the MRI including claustrophobia, metal in body, surgery within 60 days, certain implants or previous abnormal MRI results.
Evidence of Parkinson's disease as determined by the motor examination (items 18-31) of the Unified Parkinson's Disease Rating Scale (Fahn et al, 1987).
History of myocardial infarction within the previous year, or unstable cardiac disease.
Uncontrolled hypertension (systolic BP \> 170 or diastolic BP \> 100).
History of significant liver disease, clinically-significant pulmonary disease, or diabetes.
Current diagnosis of any major psychiatric disorder
Current diagnosis or history of alcoholism or substance addiction.
Regular use of any medication that may affect cognitive functioning including: centrally active beta-blockers, narcotics, Clonidine, anti-Parkinsonian medications, antipsychotics, systemic corticosteroids, medications with significant cholinergic or anticholinergic effects, anti-convulsants, or Warfarin.
Occasional use of anxiety or sleeping medications known to cause cognitive dulling will be allowed, but discouraged: chloral hydrate, non-benzodiazepine hypnotics such as: Ambien (Zolpidem) and Lunesta; or benzodiazepines such as Ativan (Lorazepam), Xanax (Alprazolam), Klonopin (Clonazepam), and Restoril (Temazepam).
Use of any of the following medications: Amitriptyline, Amiodarone, Desipramine, Fenofibrate, Flecainide, Fluconazole, Fluoxetine, Fluvastatin, Fluvoxamine, Isoniazid, Lovastatin, Ondansetron, Phenylbutazone, Probenecid, Sertraline, Sulfamethoxazole, Sulfaphenazole, Teniposide, Voriconazole, Warfarin, and Zafirlukast
Use of cognitive enhancing supplements (e.g. Ginkgo biloba).
Use of any supplement containing pomegranate or pomegranate juice.
Use of any investigational drugs within the previous month or longer, depending on drug half-life.
